Amgen lifts forecast despite obesity drug halt
The report argued Amgen raised its full-year forecast and beat revenue expectations significantly, driven by strong sales of existing treatments, despite ending development on an obesity drug.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.